Hepatoprotective effects of Scoparone in an experimental mouse model of liver fibrosis

Elçin Latife Kurtoğlu; Savaş Aslan; Safiye Göçer; Müjgan Özdemir Erdoğan; Saliha Handan Yıldız; Mustafa Solak

doi:10.26900/hsq.3106

Authors

Elçin Latife Kurtoğlu Afyonkarahisar Health Science University / Türkiye 0000-0002-8375-8399
Savaş Aslan Afyonkarahisar Health Sciences University / Türkiye 0000-0002-7073-1912
Safiye Göçer Lokman Hekim University / Türkiye 0000-0003-1787-9755
Müjgan Özdemir Erdoğan Afyonkarahisar Health Sciences University / Türkiye 0000-0002-3434-8545
Saliha Handan Yıldız Afyonkarahisar Health Sciences University / Türkiye 0000-0003-3727-3662
Mustafa Solak Biruni University / Türkiye 0000-0001-5348-9645

10.26900/hsq.3106

Abstract

Scoparone, a key ingredient isolated from Artemisia capillaris, has important therapeutic properties. In our study, it was aimed to investigate the therapeutic effects of systemic administration of Scoparone on liver fibrosis after the formation of liver fibrosis with Thioacetamide. In order to create a chronic fibrosis model, Swiss albino mice were injected intraperitoneally with Thioacetamide. Serum levels of AST and ALT were investigated in all groups, and TGF-β1, HGF and TNFAIP6 gene expressions from mRNA isolated from liver tissues were examined. According to our findings; ALT and AST levels of mouse serum samples in the fibrosis groups were significantly increased compared to the control, DMSO and Scoparone groups. It was observed that Scoparone injection in the fibrosis group decreased ALT and AST levels, but there was no statistically significant difference. While HGF gene expression was found to be significantly higher in liver mRNA samples in which Scoparone treatment was applied to the fibrous group, compared to all other groups, Scoparone injection to the fibrotic subjects caused a decrease in TGF-β1 gene expression (p<0.05). Injection of Scoparone into the liver fibrosis group caused a decrease in TNFAIP6 levels, but this decrease was not statistically significant. In conclusion; although scoparone does not completely regress fibrosis, it has been found to be beneficial and this is reflected in molecular analyzes. However, further studies are needed to determine the effect of different doses, to clarify its molecular mechanisms and targets, and to elucidate its toxicity.

Keywords:

Scoparone liver fibrosis gene expression

Downloads

Download data is not yet available.

References

White H. Neurologic manifestations of acute and chronic liver disease. CONTINUUM: Lifelong Learning in Neurology. 2014;20(3):670-80. doi:10.1212/01.CON.0000450973.84075.a7

Friedman SL. Hepatic fibrosis—overview. Toxicology. 2008;254(3):120-9. doi: 10.1016/j.tox.2008.06.013.

Parsons CJ, Takashima M, Rippe RA. Molecular mechanisms of hepatic fibrogenesis. J of Gastro and Hepatol. 2007 Jun:22 Suppl 1:S79-84. doi: 10.1111/j.1440-1746.2006.04659.x.

Maes M, Vinken M, Jaeschke H. Experimental models of hepatotoxicity related to acute liver failure. Toxicology and applied pharmacology. 2016;290:86-97. doi: 10.1016/j.taap.2015.11.016.

Wang W, Li J, Wang Z, Gao H, Su L, Xie J, vd. Oral hepatoprotective ability evaluation of purple sweet potato anthocyanins on acute and chronic chemical liver injuries. Cell Biochemistry and Biophysics. 2014;69(3):539-48. doi: 10.1007/s12013-014-9829-3.

Zhao C qing, Zhou Y, Ping J, Xu L ming. Traditional Chinese medicine for treatment of liver diseases: progress, challenges and opportunities. Journal of integrative medicine. 2014;12(5):401-8. doi: 10.1016/S2095-4964(14)60039-X.

Liu B, Deng X, Jiang Q, Li G, Zhang J, Zhang N, vd. Scoparone alleviates inflammation, apoptosis and fibrosis of non-alcoholic steatohepatitis by suppressing the TLR4/NF-κB signaling pathway in mice. International immunopharmacology. 2019;75:105797. doi: 10.1016/j.intimp.2019.105797.

Fok TF. Neonatal jaundice—traditional Chinese medicine approach. Journal of Perinatology. 2001;21(1):S98-100. doi: 10.1038/sj.jp.7210643.

Choi YH, Yan GH. Anti-allergic effects of scoparone on mast cell-mediated allergy model. Phytomedicine. 2009;16(12):1089-94. doi: 10.1016/j.phymed.2009.05.003.

Park S, Kim JK, Oh CJ, Choi SH, Jeon JH, Lee IK. Scoparone interferes with STAT3-induced proliferation of vascular smooth muscle cells. Experimental & Molecular Medicine. 2015;47(3):e145-e145. doi: 10.1038/emm.2014.113.

Jang JH, Kang KJ, Kim YH, Kang YN, Lee IS. Reevaluation of experimental model of hepatic fibrosis induced by hepatotoxic drugs: an easy, applicable, and reproducible model. 2008 Oct;40(8):2700-3. doi: 10.1016/j.transproceed.2008.07.040.

Wang S, Kim J, Lee C, Oh D, Han J, Kim TJ, vd. Tumor necrosis factor-inducible gene 6 reprograms hepatic stellate cells into stem-like cells, which ameliorates liver damage in mouse. Biomaterials. 2019;219:119375. doi: 10.1016/j.biomaterials.2019.119375.

Poynard T, Mathurin P, Lai CL, Guyader D, Poupon R, Tainturier MH, vd. A comparison of fibrosis progression in chronic liver diseases. Journal of hepatology. 2003;38(3):257-65. doi: 10.1016/s0168-8278(02)00413-0.

Mushlin PS, Gelman S. Hepatic physiology and pathophysiology. Miller’s Anesthesia 7th ed Philadelphia: Churchill Livingstone. 2010;412-24.

Newsome PN, Cramb R, Davison SM, Dillon JF, Foulerton M, Godfrey EM, vd. Guidelines on the management of abnormal liver blood tests. Gut. 2018;67(1):6-19. doi: 10.1136/gutjnl-2017-314924.

Bilgin HM, Atmaca M, Obay BD, Özekinci S, Taşdemir E, Ketani A. Protective effects of coumarin and coumarin derivatives against carbon tetrachloride-induced acute hepatotoxicity in rats. Experimental and toxicologic pathology. 2011;63(4):325-30. doi: 10.1016/j.etp.2010.02.006.

Hui Y, Wang X, Yu Z, Fan X, Cui B, Zhao T, vd. Scoparone as a therapeutic drug in liver diseases: Pharmacology, pharmacokinetics and molecular mechanisms of action. Pharmacological Research. 2020;160:105170. doi: 10.1016/j.phrs.2020.105170.

Meng X ming, Nikolic-Paterson DJ, Lan HY. TGF-β: the master regulator of fibrosis. Nature Reviews Nephrology. 2016;12(6):325-38. doi: 10.1038/nrneph.2016.48.

Murphy-Ullrich JE, Suto MJ. Thrombospondin-1 regulation of latent TGF-β activation: A therapeutic target for fibrotic disease. Matrix Biology. 2018;68:28-43. doi: 10.1016/j.matbio.2017.12.009.

Benzoubir N, Lejamtel C, Battaglia S, Testoni B, Benassi B, Gondeau C, vd. HCV core-mediated activation of latent TGF-β via thrombospondin drives the crosstalk between hepatocytes and stromal environment. Journal of hepatology. 2013;59(6):1160-8. doi: 10.1016/j.jhep.2013.07.036.

Jee MH, Hong KY, Park JH, Lee JS, Kim HS, Lee SH, vd. New Mechanism of Hepatic Fibrogenesis: Hepatitis C Virus Infection Induces Transforming Growth Factor β1 Production through Glucose-Regulated Protein 94. Ou JHJ, editör. J Virol. 2016;90(6):3044-55. doi: 10.1128/JVI.02976-15.

Jeong W, Do S, Yun H, Song B, Kim S, Kwak W, vd. Hypoxia potentiates transforming growth factor‐β expression of hepatocyte during the cirrhotic condition in rat liver. Liver International. 2004;24(6):658-68. doi: 10.1111/j.1478-3231.2004.0961.x.

Tsuchida T, Friedman SL. Mechanisms of hepatic stellate cell activation. Nature reviews Gastroenterology & hepatology. 2017;14(7):397-411. doi: 10.1038/nrgastro.2017.38.

Wang M, Zhang M, Fu L, Lin J, Zhou X, Zhou P, vd. Liver-targeted delivery of TSG-6 by calcium phosphate nanoparticles for the management of liver fibrosis. Theranostics. 2020;10(1):36. doi: 10.7150/thno.37301.

Wang S, Lee JS, Hyun J, Kim J, Kim SU, Cha HJ, vd. Tumor necrosis factor-inducible gene 6 promotes liver regeneration in mice with acute liver injury. Stem Cell Res Ther. 2015;6(1):20. doi: 10.1186/s13287-015-0019-z.

Wang S, Lee C, Kim J, Hyun J, Lim M, Cha HJ, vd. Tumor necrosis factor-inducible gene 6 protein ameliorates chronic liver damage by promoting autophagy formation in mice. Experimental & molecular medicine. 2017;49(9):e380-e380. doi: 10.1038/emm.2017.140.

Fausto N. Growth factors in liver development, regeneration and carcinogenesis. Progress in growth factor research. 1991;3(3):219-34. doi: 10.1016/0955-2235(91)90008-r.

Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nature reviews Molecular cell biology. 2003;4(12):915-25. doi: 10.1038/nrm1261.

Nakamura T, Sakai K, Nakamura T, Matsumoto K. Hepatocyte growth factor twenty years on: Much more than a growth factor. J of Gastro and Hepatol. 2011;26(s1):188-202. doi: 10.1111/j.1440-1746.2010.06549.x.

Marquardt JU, Seo D, Gómez-Quiroz LE, Uchida K, Gillen MC, Kitade M, vd. Loss of c-Met accelerates development of liver fibrosis in response to CCl4 exposure through deregulation of multiple molecular pathways. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 2012;1822(6):942-51. doi: 10.1016/j.bbadis.2012.02.012.

Matsuda Y, Matsumoto K, Ichida T, Nakamura T. Hepatocyte growth factor suppresses the onset of liver cirrhosis and abrogates lethal hepatic dysfunction in rats. The journal of biochemistry. 1995;118(3):643-9. doi: 10.1093/oxfordjournals.jbchem.a124958.

Ueki T, Kaneda Y, Tsutsui H, Nakanishi K, Sawa Y, Morishita R, vd. Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nature medicine. 1999;5(2):226-30. doi: 10.1038/5593.

Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N, Shappell S, vd. TGF-ß Signaling in Fibroblasts Modulates the Oncogenic Potential of Adjacent Epithelia. Science. 2004;303(5659):848-51. doi: 10.1126/science.1090922.

Matsumoto K, Tajima H, Okazaki H, Nakamura T. Negative regulation of hepatocyte growth factor gene expression in human lung fibroblasts and leukemic cells by transforming growth factor-beta 1 and glucocorticoids. Journal of Biological Chemistry. 1992;267(35):24917-20. PMID: 1459995

Liu Y, Michalopoulos GK, Zarnegar R. Structural and functional characterization of the mouse hepatocyte growth factor gene promoter. Journal of Biological Chemistry. 1994;269(6):4152-60. PMID: 8307976